Regional-Dependent Intestinal Permeability and BCS Classification: Elucidation of pH-Related Complexity in Rats Using Pseudoephedrine
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2
Abstract
Based on its lower Log P value relative to metoprolol, a marker for the low/high-permeability (Peff) class boundary, pseudoephedrine was provisionally classified as BCS low-permeability compound. On the other hand, following oral administration, pseudoephedrine fraction dose absorbed (Fabs) and systemic bioavailability approaches 100%. This represents a challenge to the generally recognized Peff–Fabs correlation. The purpose of this study was to elucidate the underlying mechanisms behind the confusion in pseudoephedrine’s BCS classification. Pseudoephedrine’s BCS solubility class was determined, and its physicochemical properties and intestinal permeability were thoroughly investigated, both in vitro and in vivo in rats, considering the complexity of the whole of the small intestine. Pseudoephedrine was found to be unequivocally a high-solubility compound. All of the permeability studies revealed similar phenomenon; at any given intestinal segment/pH, the permeability of metoprolol was higher than that of pseudoephedrine, however, as the intestinal region becomes progressively distal, and the pH gradually increases, pseudoephedrine’s permeability rises above that of metoprolol in the former segment. This unique permeability pattern likely explains pseudoephedrine’s complete absorption. In conclusion, pseudoephedrine is a BCS Class I compound; no discrepancy between Peff and Fabs is involved in its absorption. Rather, it reflects the complexity behind Peff when considering the whole of the intestine. We propose to allow high-permeability classification to drugs with Peff that matches/exceeds the low/high class benchmark anywhere throughout the intestinal tract and not restricted necessarily to the jejunum.
Authors and Affiliations
Moran Fairstein, Rotem Swissa, Arik Dahan
Keywords
Related Articles
- EP ID EP681108
- DOI 10.1208/s12248-013-9462-x
- Views 96
- Downloads 0
Validation of a Ligand Binding Assay Using Dried Blood Spot Sampling
Dried blood spots (DBS) technology has been introduced as a microsampling alternative to traditional plasma or serum sampling for pharmacokinetics or toxicokinetics evaluation. The application of DBS has been established...
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): Preparation and characterization
Low molecular weight protamine (LMWP) appears to be a promising solution for heparin neutralization without the protamine-associated catastrophic toxic effects. The feasibility of this hypothesis was proven previously by...
Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans
Pharmacokinetic–pharmacodynamic (PK–PD) modeling greatly enables quantitative implementation of the “learn and confirm” paradigm across different stages of drug discovery and development....
Commentary: Current Perspectives on the Aggregation of Protein Drugs
In Silico Evaluation of the Potential Impact of Bioanalytical Bias Difference between Two Therapeutic Protein Formulations for Pharmacokinetic Assessment in a Biocomparability Study
Formulation changes at later stages of biotherapeutics development require biocomparability (BC) assessment. Using simulation, this study aims to determine the potential effect of bias difference observed between the two...